Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis


The World Health Organization estimates that 65 million people worldwide have moderate to severe COPD. COPD is a major cause of disability and is expected to become the leading cause of death globally within the next two decades. There is no cure for COPD. There are treatments available for doctors to prescribe, including treatments called maintenance therapies to help maintain regular breathing. However, even with the combination of therapies, some people still have COPD symptoms or experience COPD exacerbations, which can result in a hospital admission. Napa Research has a clinical research study aimed at reducing the occurrence of COPD exacerbations with the use of study medication.

Mode of administration:

A single inhaler- Inhaled corticosteroid (ICS) with either a LAMA (long-acting muscarinic antagonist, a LABA (long-acting beta-2 agonist) or both.

The study duration: 55 weeks

Participants will attend 13 study site visits and received 2 wellness check phone calls after study.

Compensation package includes:

$70 for screening

$70 for each visit to study site

All study medication, assessments and examinations are free to the participants.

Inclusion Questions:

Has the patient been diagnosed with COPD by a Pulmonologist or PCP? (YES/ NO)

Is the patient currently taking medication for COPD?

Has the patient had a COPD exacerbation in the past 12months?

Is the patient a current or ex-smoker?

Patient’s other medical conditions:

Sign Up For Clinical Trials Now, Cash Payments for Most Studies Up to $1500, Free Medical Care